The global hunter syndrome treatment market size is estimated to reach a value of USD 1.4 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 7.6% during the forecast period. Rising patient population living with Hunter syndrome, increasing healthcare expenses, and potential approval of pipeline drugs worldwide are some of the major factors fueling market growth.
Hunter syndrome, which is also known as mucopolysaccharidosis type II (MPS II), is caused by iduronate-2-sulfatase enzyme deficiency. The treatment mainly focuses on management of symptoms, indications, and disease progression-associated complications, since there is no permanent cure for Hunter syndrome. Existing treatment includes enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT). Disease diagnosis is usually determined by a blood test for iduronate-2-sulfatase deficiency and occurs early in life based on the appearance of skeletal abnormalities.
Enzyme replacement therapy held the largest share among current treatment options in the market. This can be attributed to strong revenue generated by Shire’s ELAPRASE, an ERT prescribed worldwide to improve walking capacity and reduce spleen volume in patients of 5 years of age and older.
North America led the Hunter syndrome treatment market in 2017 with a share of close to 40.0%. This can be attributed to developed healthcare facilities in the region and increased investment in R&D of novel therapies. While novel treatments including ERTs and HSCTs are gaining penetration in developed markets, high cost of therapy poses as a hurdle in developing regions.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the study suggest:
- Hunter syndrome affects around one per 160,000 males. It is an X-linked recessive disorder and women are far less at a risk of developing this disease
- The enzyme replacement therapy segment acquired the largest share in 2017 and is expected to hold its leading position through the forecast period due to increased adoption of ELAPRASE and potential approval of Hunterase worldwide
- North America dominated the Hunter syndrome treatment market in 2017 due to well-established healthcare infrastructure and favorable reimbursement policies
- The APAC region is expected to witness the fastest growth due to rising disease cohort driven by increasing healthcare expenses
- Some of the key players in the market are Shire Plc.; GC Pharma; JCR Pharmaceuticals Co Ltd.; RegenxBio Inc.; Sangamo Therapeutics; ArmaGen Inc.; Inventiva; Denali Therapeutics Inc.; Esteve; and Bioasis Technologies Inc.
No comments:
Post a Comment